HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2

Bartlett, J.M.S.; Ahmed, I.; Regan, M.M.; Sestak, I.; Mallon, E.A.; Dell'Orto, P.; ... ; Translational Aromatase Inhibitor (2017)

Article / Letter to editor

• Breast cancer
• HER2
• Prediction
• Aromatase inhibitor
• Meta-analysis

• All authors: Bartlett, J.M.S.; Ahmed, I.; Regan, M.M.; Sestak, I.; Mallon, E.A.; Dell'Orto, P.; Thurlimann, B.; Seynaeve, C.; Putter, H.; Velde, C.J.H. van de; Brookes, C.L.; Forbes, J.F.; Viale, G.; Cuzick, J.; Dowsett, M.; Rea, D.W.; Translational Aromatase Inhibitor
• Date: 2017-07-31
• Journal: European Journal of Cancer
• Volume: 79
• Pages: 129 - 138
• DOI: doi:10.1016/j.ejca.2017.03.033